Zentiva announce that it have extended strategic partnership with Adalvo, signing a licensing deal for three molecules, within Europe. The products are indicated in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.38 RON | +1.20% | +3.68% | +15.75% |
1st Jan change | Capi. | |
---|---|---|
+15.75% | 509M | |
+18.67% | 43.74B | |
+21.99% | 22.26B | |
+16.41% | 14.9B | |
+9.03% | 13.39B | |
+40.48% | 12.12B | |
-9.64% | 6.92B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+12.41% | 5.47B |
- Stock Market
- Equities
- SCD Stock
- News Zentiva S.A.
- Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology